U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07052760) titled 'Imaging of Solid Tumors Using DLL3 SPECT' on June 28.
Brief Summary: This is a single arm, pilot trial that evaluates the ability of a novel imaging agent (111In-ABD147) to detect metastatic cancer in participants with solid tumors. 111In-ABD147 is a high affinity Delta-like ligand 3 (DLL3) antigen binding domain fused to an engineered humanized Fc to create an antibody (VHH-Fc) that is bio-conjugated with a DOTA linker-chelator to a 111In radiometal. DLL3 is expressed on a variety of tumors, particularly those with neuroendocrine features.
Study Start Date: July 31
Study Type: INTERVENTIONAL
Condition:
Solid Tumor Cancer
Castrat...